Table 4: Results of the linear model for saccadic peak velocity change from baseline and log body sway change from baseline by treatment with treatment by SPV change from baseline as interaction.

TreatmentΔSPV-relative relationItemEstimate of treatmentEstimate of lorazepam value

TPA023 1.5 mgΔSway-ΔSPVSlope−0.00048−0.00305<0.0001
Intercept−0.013160.1292<0.0001
ΔVASalertness-ΔSPVSlope0.033120.1260.0001
Intercept0.4551−4.47390.0021

TPACMP2 0.75 mgΔSway-ΔSPVSlope−0.00027−0.00305<0.0001
Intercept0.037840.12920.0009
ΔVASalertness-ΔSPVSlope0.098840.1260.2525
Intercept−1.4465−4.47390.0397

SL65.1498 25 mgΔSway-ΔSPVSlope−0.00128−0.003050.0003
Intercept0.02220.1292<0.0001
ΔVASalertness-ΔSPVSlope0.041930.1260.0009
Intercept0.2453−4.4739<0.0001
ΔSmooth-ΔSPVSlope0.015540.1099<0.0001
Intercept−1.4483−6.2553<0.0001

Alprazolam 1 mgΔSway-ΔSPVSlope−0.00204−0.003050.0667
Intercept0.0017880.1292<0.0001
ΔVASalertness-ΔSPVSlope0.07340.1260.0763
Intercept−0.628−4.47390.0254
ΔTrack-ΔSPVSlope0.07470.05720.1545
Intercept0.3023−4.0742<0.0001
ΔSmooth-ΔSPVSlope0.080770.10990.2808
Intercept−1.4025−6.25530.0002

Zolpidem 10 mgΔSway-ΔSPVSlope−0.0033−0.003050.7336
Intercept0.060140.12920.0127
ΔVASalertness-ΔSPVSlope0.15260.1260.5231
Intercept−3.2697−4.47390.5219
ΔTrack-ΔSPVSlope0.04890.05720.6240
Intercept−0.9123−4.0742<0.0001
ΔSmooth-ΔSPVSlope0.097710.10990.7412
Intercept−3.8439−6.25530.0815